An Initiative of AVAC

Zambia

A snapshot of PrEP scale-up, registration and resources for Zambia.

  • 200-400
    Estimated Number of Current PrEP Users

    Aggregates numbers reported from demonstration projects, PEPFAR dashboard and program/country reports where available. This is presented as a range due to difficulty in tracking precise numbers and possible double reporting.

  • 1,500-2,000
    Aggregate Target Number of PrEP Users from All Projects (Planned & Ongoing)

    Sum of the targets available at the quarterly data review. National targets put forward by governments may be aspirational and/or indicative of estimated need; or they may be low or non-existent if PrEP is solely available via demonstration projects. For this reason, a calculation of current PrEP users as a percentage of aggregate target will not accurately reflect progress. Additionally, some programs set targets on an annual basis while targets from other programs may extend over multiple years.

  • 1,700
    PEPFAR PrEP Target in COP 2018

    Targets are set by PEPFAR country teams on an annual basis. Targets do not indicate funding is available for PrEP.

Data Updated: September 30, 2018

Drug Registration Status

  • Gilead's Truvada (TDF/FTC) registration
    Approved
  • Generic versions of TDF/FTC for prevention
    Approved

Types of Delivery Projects

  • Large-scale implementation initiative — funded/implementer involvement and investment in some or all steps related to comprehensive introduction that may or may not use government clinics as the primary service delivery point – e.g., Kenya’s Jilinde program.

Research, Demonstration and Implementation Projects

Policy Framework

Funding

  • The Bill & Melinda Gates Foundation
  • Nike Foundation
  • PEPFAR

Eligibility Criteria

Oral PrEP is the use of antiretroviral (ARV) drugs before HIV exposure by people who are not infected with HIV to block the acquisition of HIV. Twelve trials on the effectiveness of oral PrEP have been conducted among serodiscordant couples, heterosexual men, women, men who have sex with men, people who inject drugs and transgender women. Where adherence has been high, significant levels of efficacy have been achieved, showing the value of this intervention as part of combination prevention approaches. WHO recommends oral PrEP containing TDF should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention approaches.

Recommendations:

  • Oral PrEP should be initiated to negative partner in a serodiscordant relationship whose HIV positive partner has refused to initiate cART.
  • Persons engaged in high-risk activities may also be considered for PrEP.
  • HIV testing is required before PrEP is offered.
  • Repeat HIV testing is recommended while PrEP is taken every three months.
  • The frequent HIV testing during PrEP use should also ideally become an opportunity for STI screening and management.
  • Those diagnosed HIV positive should be maintained on the same regimen.
  • PrEP should be provided as part of the combination prevention package (with condom use, HTS, family planning, STI testing etc).

Resources for Zambia